Are you an EPFL student looking for a semester project?
Work with us on data science and visualisation projects, and deploy your project as an app on top of Graph Search.
Concept
New Drug Application
Summary
The Food and Drug Administration's (FDA) New Drug Application (NDA) is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing. Some 30% or less of initial drug candidates proceed through the entire multi-year process of drug development, concluding with an approved NDA, if successful.
The goals of the NDA are to provide enough information to permit FDA reviewers to establish the complete history of the candidate drug. Among facts needed for the application are:
Patent and manufacturing information
Drug safety and specific effectiveness for its proposed use(s) when used as directed
Reports on the design, compliance, and conclusions of completed clinical trials by the Institutional Review Board
Drug susceptibility to abuse
Proposed labeling (package insert) and directions for use
Exceptions to this process include voter driven initiatives for medical marijuana in certain states.
To legally test the drug on human subjects in the U.S., the maker must first obtain an Investigational New Drug (IND) designation from FDA. This application is based on nonclinical data, typically from a combination of in vivo and in vitro laboratory safety studies, that shows the drug is safe enough to test in humans. Often the "new" drugs that are submitted for approval include new molecular entities or old medications that have been chemically modified to elicit differential pharmacological effects or reduced side effects.
The legal requirement for approval is "substantial" evidence of effectiveness demonstrated through controlled clinical trials.
This standard lies at the heart of the regulatory program for drugs. Data for the submission must come from rigorous clinical trials.
The trials are typically conducted in three phases:
Phase 1: The drug is tested in 20 to 100 healthy volunteers to determine its safety at low doses. About 70% of candidate drugs advance to Phase 2.
Phase 2: The drug is tested for both efficacy and safety in up to several hundred people with the targeted disease.
Official source
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.
Related courses (4)
CH-604: Medicinal chemistry: concepts and case studies from the pharmaceutical industry
We will cover key concepts of Medicinal Chemistry, from identification of active chemical starting points to how they are optimized to deliver drug candidates. We will use real case studies from the p
BIO-494: Scientific project design in drug discovery
The goal of this course is to instruct the student how fundamental scientific knowledge can be applied for drug discovery and development. We will demonstrate these principles with examples, including
CH-332: Medicinal chemistry
Sitting at the crossroad of organic chemistry and medicine, this course outlines how an initial hit compound transitions into a lead candidate, and ultimately a drug, in the modern drug discovery worl
Related lectures (32)
Immunoediting of Tumors: Experimental Evidence and Mechanisms
Explores tumor immunoediting, mechanisms of tumor escape, and cancer immunotherapy, emphasizing immune response regulation and recent drug approvals.
Causality and Clinical Studies
Explores causality, clinical studies, new drug evaluation, confounding factors, and data analysis methods.
Pharmacogenetics: Drug Response and Genetic Variability
Delves into pharmacogenetics, exploring genetic influences on drug response variability and metabolism.